# Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)

> **NCT02105467** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 421 (actual)

## Conditions studied

- Chronic Hepatitis C Virus

## Interventions

- **DRUG:** Grazoprevir 100mg / Elbasvir 50 mg FDC
- **DRUG:** Placebo to Grazoprevir / Elbasvir 50 mg FDC

## Key facts

- **NCT ID:** NCT02105467
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-05
- **Primary completion:** 2015-02-26
- **Final completion:** 2015-09-06
- **Target enrollment:** 421 (ACTUAL)
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02105467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02105467, "Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02105467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*